BiondVax Pharmaceuticals Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was ILS 12.85 million compared to ILS 11.99 million a year ago. Basic loss per share from continuing operations was ILS 8 compared to ILS 12 a year ago.
For the six months, net loss was ILS 22.27 million compared to ILS 20.18 million a year ago. Basic loss per share from continuing operations was ILS 12 compared to ILS 16 a year ago.